Bloody nipple discharge with papilloma on core — atypia fork, predictors and excision plan

Case narrative

A 41-year-old woman reports intermittent bloody discharge from a single duct with a 12 mm retroareolar intraductal mass on sonography. Core-needle biopsy shows intraductal papilloma with atypia, concordant with imaging. She asks whether surveillance is safe, what makes upgrade more likely, and what surgery involves — and what you would have advised had the core shown papilloma without atypia.

What the candidate must do

Split on atypia first. State the pooled fork: benign intraductal papilloma upgrades at 5.0% while atypical disease upgrades at 36.0% — so her atypical result sits on the excision side of the ladder, not the surveillance side.^[11]

Place the historical context. Across 34 studies with 2236 nonmalignant papillary lesions at core-needle biopsy, 346 upgraded for a pooled underestimation of 15.7% — the background number behind routine excision before the benign-versus-atypical split sharpened it.^[12]

Apply her predictors. Bloody nipple discharge is one of ten reported upgrade factors for benign disease (with higher BI-RADS categories, mass-calcification patterns, discordance, peripheral location, palpability and larger size), carrying factor-associated upgrade of 7.3 to 31.1% — and her discharge plus atypia together reinforce excision.^[11]

State the operation. For papillary lesions with atypia complete excisional surgery is recommended — excise completely with radiologic-pathologic correlation, rather than vacuum sampling alone, and counsel that papilloma with atypia continues to warrant excision under current synthesis.^[16][20]

Contrast the benign-concordant pathway she is not on. For concordant intraductal papilloma without atypia the pooled underestimation is 1.4% and surveillance is concluded safe; in the King's College series papillary lesions without atypia upgraded in 8 of 179 excisions (4%) with none invasive — the surveillance arm she would have occupied without atypia.^[10][9]

Frame the B3 context and follow-up. Belgian national data upgrade B3 lesions in 19.0% after core-needle and 14.9% after vacuum-assisted biopsy, with papillary lesions at 10.4% and 12.5% respectively — so her lesion travels a defined B3 pathway with multidisciplinary discussion, complete excision now, and surveillance after, including attention to any coexisting atypia as a long-term risk marker.^[6][20]